Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.56 |
| ▸ | TPH1 | P17752 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456664 | 1.00 | S1PR1 (0.56) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL3456144 | 0.87 | S1PR1 (0.52) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL3456844 | 0.86 | S1PR1 (0.52) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL4741310 | 0.84 | S1PR1 (0.54) | S1PR1S1PR4S1PR5S1PR3 | |
| SCHEMBL4741601 | 0.83 | S1PR1 (0.52) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL4741518 | 0.83 | S1PR1 (0.57) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL13269548 | 0.83 | NPC1 (0.46) | S1PR1S1PR4S1PR5S1PR3NPC1 | |
| SCHEMBL28776656 | 0.83 | S1PR1 (0.54) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL5378065 | 0.82 | S1PR1 (0.58) | S1PR1S1PR4S1PR5S1PR3TPH1 | |
| SCHEMBL16591181 | 0.82 | S1PR1 (0.50) | S1PR1S1PR4S1PR5S1PR3TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048103-B1 | COMPOUND FOR IMMUNE MODULATION, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SUZHOU CONNECT BIOPHARMACEUTICALS LTD (CN) | 2020-03-11 | — | — | EP | disclosed |
| US-10280158-B2 | Immune adjustment compound, use thereof and pharmaceutical composition comprising same | SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-10280158-B2 | Immune adjustment compound, use thereof and pharmaceutical composition comprising same | SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20160347745-A1 | IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) | 2016-12-01 | — | — | US | disclosed |
| US-20160347745-A1 | IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) | 2016-12-01 | — | — | US | disclosed |
| US-20160347745-A1 | IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) | 2016-12-01 | — | — | US | disclosed |
| EP-3048103-A1 | IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048103-A1 | IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. (CN) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015039587-A1 | IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 苏州康乃德生物医药有限公司 | 2015-03-26 | — | — | WO | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| EP-1826197-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-7199142-B2 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1549640-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004035538-A1 | PROCESS FOR MAKING AZETIDINE-3-CARBOXYLIC ACID | MERCK & CO., INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003105771-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347745-A1 | IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR4 4/4885S1PR5 3/4885 |
| US-10280158-B2 | Immune adjustment compound, use thereof and pharmaceutical composition comprising same | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR4 4/4885S1PR5 3/4885 |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | EDNRA, OXGR1, EDNRB | S1PR1 217/4885S1PR4 449/4885S1PR5 281/4885 |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCND1, CCND2, CCND3 | S1PR1 104/4885S1PR4 254/4885S1PR5 248/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | S1PR1 396/4885S1PR4 588/4885S1PR5 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.